Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Prostate Cancer

Free Subscription 20.07.2026 1 AJR Am J Roentgenol 2 BJU Int 2 BMC Cancer 1 BMC Urol 1 Br J Cancer 1 Cancer Lett 1 Clin Cancer Res 14 Eur Urol 1 Int J Oncol 4 Int J Radiat Oncol Biol Phys 2 Int J Urol 1 Invest Radiol 3 J Nucl Med 3 J Urol 1 Oncogene 1 PLoS One 1 Prostate 1 Radiol Artif Intell 1 Urol Int 1 Urology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. CHOI WP, Almaguel FG, Franquet-Elia E, Ghai S, et al
   Optimal Imaging Strategies After Negative PSMA PET/CT Results in Patients With Prostate Cancer Biochemical Recurrence: AJR Expert Panel Narrative Review.
   AJR Am J Roentgenol. 2026 Jul 15. doi: 10.2214/AJR.26.35081.
   PubMed         Abstract available
   
   

   
   BJU Int

2. LIU L, Huang JF, Shi RH, Yang L, et al
   Automated recognition of surgical phases in robot-assisted radical prostatectomy using a Hiera-based vision transformer.
   BJU Int. 2026;138:324-333.
   PubMed         Abstract available
   
   
3. CARLL J, Walbaum J, Delgado C, Berg E, et al
   Guideline of guidelines: pelvic lymph node dissection at time of radical prostatectomy.
   BJU Int. 2026;138:208-218.
   PubMed         Abstract available
   
   

   
   BMC Cancer

4. AKINNOLA OO, Olaniyan AI, Adeboye BA, Akinyosoye AD, et al
   Impact of immunotherapy as a monotherapy or in combination with conventional therapies on regulatory T-cell (Treg) modulation in prostate cancer: a systematic review.
   BMC Cancer. 2026 Jul 17. doi: 10.1186/s12885-026-16550.
   PubMed         Abstract available
   
   
5. NGUYEN HT, Vu MD, Nguyen DD, Dinh PN, et al
   Next-generation sequencing-based characterization of BRCA1/2 variants across multiple tumor types in Vietnamese patients.
   BMC Cancer. 2026;26:858.
   PubMed         Abstract available
   
   

   
   BMC Urol

6. DE ALMEIDA LUZ M, Pereira J, Kool R, Matheus WE, et al
   Biochemical recurrence following definitive treatment of prostate cancer in Brazil: a retrospective cohort study.
   BMC Urol. 2026 Jul 13. doi: 10.1186/s12894-026-02249.
   PubMed         Abstract available
   
   

   
   Br J Cancer

7. PENG Z, Hodgson K, Fisher M, Mei S, et al
   Targeting Siglec-engaging immunosuppressive sialoglycans to suppress prostate cancer bone metastasis.
   Br J Cancer. 2026 Jul 13. doi: 10.1038/s41416-026-03544.
   PubMed         Abstract available
   
   

   
   Cancer Lett

8. LIANG S, Zheng Y, Wu X, Ji F, et al
   A novel lncRNA HUDRPC suppresses ferroptosis via the DDX5/DDIT3 pathway to promote docetaxel resistance in prostate cancer.
   Cancer Lett. 2026;657:218727.
   PubMed         Abstract available
   
   

   
   Clin Cancer Res

9. WEBB AJ, Harper E, Rattay T, Aguado-Barrera ME, et al
   Circadian genotypes in PER3 and time of prostate cancer radiotherapy interact to affect risk of late side-effects.
   Clin Cancer Res. 2026 Jul 13. doi: 10.1158/1078-0432.CCR-26-0268.
   PubMed         Abstract available
   
   

   
   Eur Urol

10. SHORE ND, Freedland SJ
    Reply to Francesco Barletta, Chiara Mercinelli, Francesco Montorsi, et al. re: Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.019.
    Eur Urol. 2026 Jul 10:S0302-2838(26)02156-1. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    
11. HE BM, Zhang K, Zhou Z, Chen X, et al
    Cognitive Versus Software-based Fusion Targeted Biopsy for the Diagnosis of Clinically Significant Prostate Cancer: A Multicenter, Randomized, Noninferiority Trial (IMAGINATION).
    Eur Urol. 2026 Jul 10:S0302-2838(26)02243-8. doi: 10.1016/j.eururo.2026.
    PubMed         Abstract available
    
    
12. LIGHT A, Peters M, Gopalakrishnan A, Mayor N, et al
    Oncological Outcomes Following Focal HIFU and Cryotherapy for Treatment of Nonmetastatic Prostate Cancer in the United Kingdom: An Updated Analysis of 3477 Patients from the Prospective HEAT and ICE Registries.
    Eur Urol. 2026 Jul 10:S0302-2838(26)02169-X. doi: 10.1016/j.eururo.2026.
    PubMed         Abstract available
    
    
13. SHIN YS, Kim JH
    Re: David-Dan Nguyen, Borna Tadayon Najafabadi, Lauren Lin, et al. Effect of Prostate Cancer Screening with Prostate-specific Antigen Testing on Long-term Prostate Cancer-specific Mortality: A Systematic Review and Meta-analysis of Randomized Controll
    Eur Urol. 2026 Jul 11:S0302-2838(26)02255-4. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    
14. KRILAVICIUTE A, Becker N, Carlsson SV, Kaaks R, et al
    Confirmation of Prostate-specific Antigen (PSA) Values Improves Prostate Cancer Screening in Early Middle-Aged Men - Data from the PROBASE Trial.
    Eur Urol. 2026 Jul 13:S0302-2838(26)02239-6. doi: 10.1016/j.eururo.2026.
    PubMed         Abstract available
    
    
15. HEIDEGGER I
    Re: Luka Cavka, Subhiksha Nandakumar, Qingqing Wu, et al. IDH1 Mutations Are Associated with Favorable Outcomes in Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.014.
    Eur Urol. 2026 Jul 13:S0302-2838(26)02257-8. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    
16. MESSINA E, Sciarra A, La Torre G, Panebianco V, et al
    Re: De Luca et al. Primary Noncontrast Magnetic Resonance Imaging for Prostate Cancer Screening: A Randomized Clinical Trial (PROSA). Eur Urol 2026;89:246-57.
    Eur Urol. 2026 Jul 14:S0302-2838(26)02234-7. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    
17. CORNFORD P, van den Bergh RCN, Briers E, Chiu P, et al
    EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2026 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent.
    Eur Urol. 2026 Sep 1:S0302-2838(26)02114-7. doi: 10.1016/j.eururo.2026.
    PubMed         Abstract available
    
    
18. TILKI D, van den Bergh RCN, Briers E, Chiu P, et al
    EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2026 Update: Treatment of Relapsing and Metastatic Prostate Cancer.
    Eur Urol. 2026 Jul 15:S0302-2838(26)02116-0. doi: 10.1016/j.eururo.2026.
    PubMed         Abstract available
    
    
19. O'CALLAGHAN ME, Selth L, Wittert G
    Re: Testosterone Treatment in Prostate Cancer Survivors with Hypogonadism: A Randomized Clinical Trial.
    Eur Urol. 2026 Jul 15:S0302-2838(26)02262-1. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    
20. BELLIVEAU C, Kishan AU, Calais J, Plouznikoff N, et al
    Re: [177Lu]-PSMA-617-PSMA-617 in Oligometastatic Hormone Sensitive Prostate Cancer (BULLSEYE): An Open-label, Randomised, Phase 2 Study.
    Eur Urol. 2026 Jul 15:S0302-2838(26)02264-5. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    
21. URSO L, Giannarini G, Girometti R, Crestani A, et al
    Re: Effect of [68Ga]Ga-PSMA-11 PET-CT in the Diagnosis of Prostate Cancer in Men with Equivocal or Clinically High-risk Non-suspicious Findings in Multiparametric MRI (PRIMARY2): A Multicentre, Non-inferiority, Phase 3, Randomised Controlled Trial.
    Eur Urol. 2026 Jul 16:S0302-2838(26)02268-2. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    
22. MAY M, Burger M, Brookman-May SD
    Re: Prostate-specific Membrane Antigen Imaging and Initial Treatment for Prostate Cancer.
    Eur Urol. 2026 Jul 16:S0302-2838(26)02261-X. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    
23. AL-KHANATY A, Delgado C, Berg E, Sandhu K, et al
    RE: Perioperative Apalutamide in High-Risk Localized Prostate Cancer.
    Eur Urol. 2026 Jul 16:S0302-2838(26)02260-8. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    

    
    Int J Oncol

24. BAXEVANIS CN, Stokidis S, Fortis SP, Goulielmaki M, et al
    Immunoediting and precision biomarkers in prostate cancer: The emerging role of liquid biopsy, immune contexture and HLA genotype (Review).
    Int J Oncol. 2026;69:104.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

25. COZZI S, Brenna D, Vial N, Roukoz C, et al
    Beyond Prostate-Specific Antigen and Conventional Imaging: How Prostate-Specific Membrane Antigen Positron Emission Tomography Is Transforming Postradiation Therapy Monitoring in Oligometastatic Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2026;125:1466-1470.
    PubMed        
    
    
26. POON DM, Wong K, Lam D, Johnson D, et al
    Acute toxicity and quality of life with stereotactic body radiotherapy versus conventional fractionated intensity-modulated radiotherapy to the prostate and pelvis in high-risk prostate cancer (SRAM): A randomized phase II trial.
    Int J Radiat Oncol Biol Phys. 2026 Jul 10:S0360-3016(26)03941.
    PubMed         Abstract available
    
    
27. LALL R, Evans M, Seo Y, Niknejad A, et al
    Continuous, Preclinical Activity Reconstruction in (177)Lu-based Radiopharmaceutical Therapy Using a Sparse Uncollimated gamma-Sensor Network.
    Int J Radiat Oncol Biol Phys. 2026;125:1522-1533.
    PubMed         Abstract available
    
    
28. SINGH M, Ghosh S, Katdare A, Agrawal A, et al
    PSA and PSMA Kinetics After PSMA-PET and MR Guided Prostate Stereotactic Body Radiation Therapy With Focal Boost: Results From the Phase 2 PROBE Trial.
    Int J Radiat Oncol Biol Phys. 2026;125:1471-1479.
    PubMed         Abstract available
    
    

    
    Int J Urol

29. SAKAMOTO S, Yamamoto K, Yamamoto H, Hatakeyama S, et al
    A Nationwide Descriptive Analysis of Real-World Outcomes After Radical Prostatectomy in Japan Using the National Clinical Database.
    Int J Urol. 2026;33:e70567.
    PubMed         Abstract available
    
    
30. MATSUO T, Ozawa Y, Yorozu A, Hattori S, et al
    Prognostic Impact and Metastasis Propensity of Grade Group 5 Prostate Cancer Following Permanent Seed Implantation Brachytherapy-Based Trimodality Therapy: Implications for Intensified Staging and Systemic Therapy Optimization.
    Int J Urol. 2026;33:e70574.
    PubMed         Abstract available
    
    

    
    Invest Radiol

31. KADER A, Mangarova DB, Godde H, Ranner-Hafferl MLHH, et al
    Elastin-Specific Molecular Magnetic Resonance Imaging Reveals Spatiotemporal Extracellular Matrix Remodeling at the Tumor-Stroma Interface During Prostate Cancer Progression.
    Invest Radiol. 2026 Jul 15. doi: 10.1097/RLI.0000000000001302.
    PubMed         Abstract available
    
    

    
    J Nucl Med

32. RAVI P, Zhong C, Perez KJ, Xie W, et al
    Clinical Impact and Dynamics of Clonal Hematopoiesis with (177)Lu-PSMA-617 Therapy in Advanced Prostate Cancer.
    J Nucl Med. 2026 Jul 16:jnumed.126.272125. doi: 10.2967/jnumed.126.272125.
    PubMed         Abstract available
    
    
33. HERRMANN K, Rahbar K, Eiber M, Sparks R, et al
    Update to "Renal and Multiorgan Safety of (177)Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy".
    J Nucl Med. 2026 Jul 16:jnumed.126.265448e. doi: 10.2967/jnumed.126.265448.
    PubMed        
    
    
34. MIYAHIRA A, Czernin J
    An Immunologist's Path Toward Advancing the Scientific Mission of the Prostate Cancer Foundation: Andrea Miyahira Talks with Johannes Czernin About the Role of the Prostate Cancer Foundation and Cancer Treatment.
    J Nucl Med. 2026 Jul 16:jnumed.126.273264. doi: 10.2967/jnumed.126.273264.
    PubMed        
    
    

    
    J Urol

35. TANEJA SS
    Updating of the AUA/ASTRO prostate cancer guidelines - a constant work in progress.
    J Urol. 2026 Jul 17:101097JU0000000000005225. doi: 10.1097/JU.0000000000005225.
    PubMed        
    
    
36. SCARPATO KR, Cookson MS, Dreicer R, Sayan M, et al
    Advanced Prostate Cancer: AUA/SUO Guideline Amendment (2026). Part II: Evaluation and Management of Metastatic Castration-Resistant Prostate Cancer.
    J Urol. 2026 Jul 16:101097JU0000000000005219. doi: 10.1097/JU.0000000000005219.
    PubMed         Abstract available
    
    
37. SCARPATO KR, Cookson MS, Dreicer R, Sayan M, et al
    Advanced Prostate Cancer: AUA/SUO Guideline Amendment (2026) Part I: Evaluation and Treatment of Biochemically Recurrent (Following Exhaustion of Local Therapy) and Metastatic Hormone-Sensitive Prostate Cancer.
    J Urol. 2026 Jul 16:101097JU0000000000005220. doi: 10.1097/JU.0000000000005220.
    PubMed         Abstract available
    
    

    
    Oncogene

38. YANG R, Ge Q, Wu F, Long M, et al
    METTL5-mediated rRNA modification controls prostate cancer progression through the IRF7/DNA2 axis and mitophagy regulation.
    Oncogene. 2026 Jul 13. doi: 10.1038/s41388-026-03867.
    PubMed         Abstract available
    
    

    
    PLoS One

39. AKYNKOZHAYEV B, Christoffersen B, Lantz A, Nordstrom T, et al
    Joint modelling of PSA dynamics and prostate cancer risks: A population-based study in men without prior prostate cancer.
    PLoS One. 2026;21:e0343751.
    PubMed         Abstract available
    
    

    
    Prostate

40. ONISHI K, Nakahama T, Nakai Y, Tachibana A, et al
    Evaluating Risk Factors Associating With Late Recurrence After Low-Dose-Rate Brachytherapy for Prostate Cancer Using Machine Learning.
    Prostate. 2026 Jul 16. doi: 10.1002/pros.70219.
    PubMed         Abstract available
    
    

    
    Radiol Artif Intell

41. JAISWAL A, Rinneburger M, Meyer F, Arjune S, et al
    Impact on Cost and Expert Time of Data-Efficient Deep Learning for Medical Image Segmentation.
    Radiol Artif Intell. 2026;8:e250200.
    PubMed         Abstract available
    
    

    
    Urol Int

42. MELCHIOR F, Koett M, Aigner G, Schroffenegger J, et al
    Real-World Use of Prolaris(R) to Guide Treatment Decisions in Localized Prostate Cancer Eligible for Active Surveillance.
    Urol Int. 2026 Jul 17:1-14. doi: 10.1159/000553659.
    PubMed         Abstract available
    
    

    
    Urology

43. BLANCAFLOR A, Ochsner A, Glebocki R, Westrick L, et al
    Immediate Release of Prostate Biopsy Results: Perspectives From Patients and Providers.
    Urology. 2026;213:96-100.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum